NEW YORK – Surfix Diagnostics said Wednesday that it has entered a collaboration with the Netherlands Cancer Institute and CRCbioscreen to develop improved colorectal cancer screening methods using its photonic diagnostic platform and novel biomarkers discovered by NKI.
The project, dubbed PHOBICCS, is supported by a public-private partnership grant from Health~Holland.
Investigators from CRCbioscreen and NKI had previously published data on a three-protein assay dubbed the MultitargetFIT test, which showed improvement over traditional fecal immunochemical testing.
The new biomarkers now being explored with Surfix are associated with both cancers and high-risk precursor lesions with a specific molecular profile that makes them more likely to progress to cancer.